FDA warns Lilly on Puerto Rico plant

The FDA has issued a warning letter to Eli Lilly about its API production facility in Puerto Rico, stating that the company failed to adequately investigate problems with manufacturing ingredients used to make its diabetes treatment Humalog. Letter | Report